Autonomix Medical Inc Financials
This page shows Autonomix Medical Inc (AMIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AMIX’s core mechanic is externally funded operating burn, with cash repeatedly replenished by financing as spending scales up.
In FY2026, financing inflows of$10.2M still trailed operating cash burn of-$12.3M , so fundraising was not enough to fully replenish what operations consumed. Cash therefore fell from$9.1M to$7.0M , reinforcing the FY2025 pattern that liquidity is being sustained by fresh capital rather than by self-funding activity.
The wider FY2026 loss reflects a broad operating step-up rather than a one-off balance-sheet hit, because research spending and corporate overhead both moved higher. R&D rose to
Free cash flow of
Financial Health Signals
We are recalculating Autonomix Medical Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Autonomix Medical Inc scores -18.02, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.3M) relative to total liabilities ($1.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Autonomix Medical Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Autonomix Medical Inc generates $0.73 in operating cash flow (-$12.3M OCF vs -$16.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Autonomix Medical Inc generated $0 in revenue in fiscal year 2026.
Autonomix Medical Inc's EBITDA was -$17.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 49.3% from the prior year.
Autonomix Medical Inc reported -$16.7M in net income in fiscal year 2026. This represents a decrease of 46.5% from the prior year.
Cash & Balance Sheet
Autonomix Medical Inc generated -$12.3M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 48.6% from the prior year.
Autonomix Medical Inc held $7.0M in cash against $0 in long-term debt as of fiscal year 2026.
Autonomix Medical Inc had 11M shares outstanding in fiscal year 2026.
Margins & Returns
Autonomix Medical Inc's ROE was -283.6% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 142.7 percentage points from the prior year.
Capital Allocation
Autonomix Medical Inc invested $7.1M in research and development in fiscal year 2026. This represents an increase of 51.2% from the prior year.
Autonomix Medical Inc invested $10K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 28.6% from the prior year.
AMIX Income Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $1.7M-27.2% | $2.4M+48.6% | $1.6M | N/A | $1.0M-11.1% | $1.2M+23.1% | $954K |
| SG&A Expenses | N/A | $1.6M-68.7% | $5.2M+182.7% | $1.8M | N/A | $1.7M+2.5% | $1.7M-7.6% | $1.8M |
| Operating Income | N/A | -$3.3M+55.6% | -$7.5M-120.2% | -$3.4M | N/A | -$2.7M+3.1% | -$2.8M-3.0% | -$2.8M |
| Interest Expense | N/A | $0 | $0 | $0 | N/A | $100K0.0% | $100K+143.9% | $41K |
| Income Tax | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | N/A | -$3.3M+56.2% | -$7.5M-123.3% | -$3.3M+70.8% | -$11.4M-320.7% | -$2.7M+3.4% | -$2.8M-4.0% | -$2.7M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AMIX Balance Sheet
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.6M-25.6% | $10.2M+28.7% | $7.9M-11.8% | $9.0M-8.3% | $9.8M-18.0% | $12.0M+122.5% | $5.4M-24.3% | $7.1M |
| Current Assets | $7.6M-25.6% | $10.2M+29.1% | $7.9M-12.1% | $9.0M-6.6% | $9.6M-19.5% | $11.9M+122.9% | $5.4M-24.3% | $7.1M |
| Cash & Equivalents | $7.0M-29.5% | $9.9M+32.9% | $7.5M-12.9% | $8.6M-6.0% | $9.1M-22.7% | $11.8M+129.4% | $5.2M-23.6% | $6.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.7M+3.3% | $1.6M+11.0% | $1.5M-24.3% | $2.0M+15.1% | $1.7M-24.0% | $2.2M-4.2% | $2.3M+29.7% | $1.8M |
| Current Liabilities | $1.7M+3.3% | $1.6M+11.0% | $1.5M-24.3% | $2.0M+15.1% | $1.7M-24.0% | $2.2M+78.6% | $1.3M+64.7% | $763K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $5.9M-31.1% | $8.6M+32.8% | $6.4M-8.3% | $7.0M-13.2% | $8.1M-16.6% | $9.7M+220.6% | $3.0M-42.7% | $5.3M |
| Retained Earnings | -$67.1M-4.1% | -$64.4M-5.3% | -$61.2M-13.9% | -$53.7M-6.6% | -$50.4M-6.8% | -$47.2M-6.1% | -$44.5M-6.7% | -$41.7M |
AMIX Cash Flow Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9M+2.6% | -$3.0M+22.2% | -$3.8M-46.6% | -$2.6M+68.5% | -$8.3M-258.9% | -$2.3M-44.2% | -$1.6M+13.8% | -$1.9M |
| Capital Expenditures | $3K-57.1% | $7K | $0 | $0-100.0% | $14K+180.0% | $5K | $0-100.0% | $5K |
| Free Cash Flow | -$2.9M+2.7% | -$3.0M+22.0% | -$3.8M-46.6% | -$2.6M+68.5% | -$8.3M-258.7% | -$2.3M-44.5% | -$1.6M+14.1% | -$1.9M |
| Investing Cash Flow | -$3K+57.1% | -$7K | $0 | $0+100.0% | -$14K-180.0% | -$5K | $0+100.0% | -$5K |
| Financing Cash Flow | -$35K-100.6% | $5.4M+100.9% | $2.7M+31.5% | $2.1M-76.6% | $8.8M-1.9% | $9.0M | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AMIX Financial Ratios
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -38.1%+77.5pp | -115.6%-68.1pp | -47.4%+93.4pp | -140.9%-112.9pp | -27.9%+64.8pp | -92.7%-41.7pp | -51.0% |
| Return on Assets | N/A | -31.9%+62.0pp | -93.9%-56.8pp | -37.1%+79.3pp | -116.4%-93.7pp | -22.7%+29.6pp | -52.3%-14.2pp | -38.0% |
| Current Ratio | 4.45-1.7 | 6.18+0.9 | 5.31+0.7 | 4.57-1.1 | 5.63+0.3 | 5.31+1.1 | 4.26-5.0 | 9.27 |
| Debt-to-Equity | 0.29+0.1 | 0.19-0.0 | 0.23-0.0 | 0.28+0.1 | 0.21-0.0 | 0.23-0.5 | 0.77+0.4 | 0.34 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Autonomix Medical Inc's annual revenue?
Autonomix Medical Inc (AMIX) reported $0 in total revenue for fiscal year 2026. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Autonomix Medical Inc profitable?
No, Autonomix Medical Inc (AMIX) reported a net income of -$16.7M in fiscal year 2026.
What is Autonomix Medical Inc's EBITDA?
Autonomix Medical Inc (AMIX) had EBITDA of -$17.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Autonomix Medical Inc's return on equity (ROE)?
Autonomix Medical Inc (AMIX) has a return on equity of -283.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Autonomix Medical Inc's free cash flow?
Autonomix Medical Inc (AMIX) generated -$12.3M in free cash flow during fiscal year 2026. This represents a -48.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Autonomix Medical Inc's operating cash flow?
Autonomix Medical Inc (AMIX) generated -$12.3M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Autonomix Medical Inc's total assets?
Autonomix Medical Inc (AMIX) had $7.6M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Autonomix Medical Inc's capital expenditures?
Autonomix Medical Inc (AMIX) invested $10K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Autonomix Medical Inc spend on research and development?
Autonomix Medical Inc (AMIX) invested $7.1M in research and development during fiscal year 2026.
What is Autonomix Medical Inc's current ratio?
Autonomix Medical Inc (AMIX) had a current ratio of 4.45 as of fiscal year 2026, which is generally considered healthy.
What is Autonomix Medical Inc's debt-to-equity ratio?
Autonomix Medical Inc (AMIX) had a debt-to-equity ratio of 0.29 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Autonomix Medical Inc's return on assets (ROA)?
Autonomix Medical Inc (AMIX) had a return on assets of -219.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Autonomix Medical Inc's cash runway?
Based on fiscal year 2026 data, Autonomix Medical Inc (AMIX) had $7.0M in cash against an annual operating cash burn of $12.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Autonomix Medical Inc's Altman Z-Score?
Autonomix Medical Inc (AMIX) has an Altman Z-Score of -18.02, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Autonomix Medical Inc's Piotroski F-Score?
Autonomix Medical Inc (AMIX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Autonomix Medical Inc's earnings high quality?
Autonomix Medical Inc (AMIX) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.